New Study Links Diabetes Drug Class to 45% Lower Dementia Risk
University of Galway research led by medical students highlights the neuroprotective potential of GLP-1 receptor agonists in type 2 diabetes patients.
- A systematic review and meta-analysis of 26 clinical trials involving over 160,000 participants found that GLP-1 receptor agonists significantly reduce dementia risk by 45%.
- This groundbreaking study, published in JAMA Neurology, was led by two undergraduate medical students from the University of Galway.
- The findings emphasize that the neuroprotective effects are specific to GLP-1 receptor agonists, as other glucose-lowering therapies did not show similar benefits.
- Additional analysis of nearly 400,000 health records in Florida corroborates the association between GLP-1 receptor agonists and reduced Alzheimer’s disease risk.
- Researchers are investigating how these drugs mitigate dementia risk, with early evidence pointing to reduced inflammation, insulin resistance, and vascular damage.
Women's Health 